Holen Sie sich die Stockscreener-App
33.18
5.68%
-2.10
Assembly Biosciences Inc Aktie (ASMB) Neueste Nachrichten
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks - TradingView
Why is Assembly Biosciences stock surging today? By Investing.com - Investing.com Australia
Why is Assembly Biosciences stock surging today? - Investing.com
Assembly Biosciences (ASMB) Shares U.S. Development Costs and Profits with Gilead on Herpes Treatment - GuruFocus
Assembly Bio stock gains after exercising Gilead profit option By Investing.com - Investing.com South Africa
Assembly Bio stock gains after exercising Gilead profit option - Investing.com
Assembly Bio opts into 40% U.S. profit share for herpes drug - Investing.com Canada
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program - The Manila Times
Assembly Bio opts into 40% U.S. profit share for herpes drug By Investing.com - Investing.com India
Assembly Biosciences exercises profit share option with Gilead for HSV program - TipRanks
A $75 million Gilead payment is due in Q4, while Assembly Bio expects cash to fund operations into 2029. - Stock Titan
Zacks.com featured highlights include EuroDry, RCM, Assembly Biosciences, Delcath and National Energy Services - finance.yahoo.com
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? - finance.yahoo.com
Should You Buy Assembly Biosciences (ASMB) After Golden Cross? - finance.yahoo.com
How Assembly Biosciences Inc. (ASMB) Affects Rotational Strategy Timing - Stock Traders Daily
Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going - finance.yahoo.com
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM) and Assembly Biosciences (ASMB) - The Globe and Mail
ASMB Maintained by Mizuho -- Price Target Lowered to $45 - GuruFocus
ASMB Initiates Coverage On UBS -- Price Target Announced at $52. - GuruFocus
Assembly Biosciences Price Target Announced at $52.00/Share by UBS - Moomoo
Assembly Biosciences price target raised to $53 from $45 at Mizuho - TipRanks
UBS initiates Assembly Biosciences stock with buy rating on antiviral platform - Investing.com Nigeria
Mizuho lowers Assembly Biosciences stock price target to $45 - Investing.com
Assembly Biosciences Inc (ASMB) Stock Price, Quote, News & History - Benzinga
Price to earnings forward of Assembly Biosciences, Inc. – NASDAQ:ASMB - TradingView
Certain Stock Options of Assembly Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 21-AUG-2026. - marketscreener.com
Wall Street Analysts Think Assembly Biosciences (ASMB) Could Surge 40.66%: Read This Before Placing a Bet - Zacks Investment Research
Q3 EPS Forecast for Assembly Biosciences Raised by Analyst - MarketBeat
Assembly Biosciences (NASDAQ:ASMB) Shares Gap UpShould You Buy? - MarketBeat
HC Wainwright Issues Negative Estimate for ASMB Earnings - MarketBeat
Assembly Biosciences (ASMB) Slides 8.92% to $30.01 as Key Support Comes into FocusFundamental Weighted - vinanet.vn
Assembly Biosciences (NASDAQ:ASMB) Earns "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Assembly Biosciences stock rating at buy - Investing.com
H.C. Wainwright reiterates Assembly Biosciences stock rating at buy By Investing.com - Investing.com India
ASMB Reiterated by HC Wainwright & Co. -- Maintains Price Target at $50 - GuruFocus
Assembly Biosciences reports Q2 EPS (20c), consensus (52c) - TipRanks
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal - Seeking Alpha
Assembly Biosciences, Inc. (NASDAQ:ASMB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assembly Biosciences (ASMB) sees Paradigm BioCapital report 7.8% ownership stake - Stock Titan
Why (ASMB) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings - MarketBeat
Assembly Biosciences, Inc.: Revenue and Earnings Analysts Forecasts Revisions | ASMB | US0453962070 - marketscreener.com
Assembly Biosciences earnings beat by $0.53, revenue topped estimates - Investing.com Nigeria
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Assembly Biosciences (NASDAQ:ASMB) Issues Quarterly Earnings Results, Beats Expectations By $0.52 EPS - MarketBeat
Assembly Biosciences (ASMB) boosts cash to $320M and narrows loss - Stock Titan
Assembly Biosciences: Q2 Earnings Snapshot - AOL.com
Assembly Biosciences: Cash Runway Projected Into 2029 >ASMB - Moomoo
Assembly Biosciences Projects Operations Funded Into 2029 With $75M Gilead Payment Due - Stock Titan
Assembly Biosciences (ASMB) Surges 9.6% to $29.65 as Biotech Buying Pressure IntensifiesGEX Level - vinanet.vn
Assembly Biosciences (ASMB): Janus Henderson Group discloses 1,359,514-share, 6.9% beneficial stake - Stock Titan
Assembly Biosciences (ASMB) Edges Higher to $26.83 Amid ConsolidationTrend Reversal Picks - dars.gov.et
Farallon Capital Management Expands Stake in Assembly Biosciences Inc (ASMB) with Strategic Add - GuruFocus
ASMB Q2'26 Earnings: revenue estimate is 8.60M USD - TradingView
Farallon funds disclose 8.1% Assembly Biosciences (ASMB) stake plus over 1M warrants - Stock Titan
Understanding Momentum Shifts in (ASMB) - Stock Traders Daily
Assembly Biosciences Inc (ASMB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Assembly Biosciences (ASMB) Rallies Nearly 3% as Shares Approach Key Resistance LevelInitial Balance - vinanet.vn
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):